ProfileGDS5678 / 1418083_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 88% 86% 85% 86% 86% 84% 87% 86% 87% 87% 86% 84% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.649487
GSM967853U87-EV human glioblastoma xenograft - Control 26.8871888
GSM967854U87-EV human glioblastoma xenograft - Control 36.6212186
GSM967855U87-EV human glioblastoma xenograft - Control 46.5574685
GSM967856U87-EV human glioblastoma xenograft - Control 56.6168586
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.2576886
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0040784
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5745787
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4345586
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6926587
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5993187
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.6440786
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.2742184
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.7032887